SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is facing intense scrutiny and extreme market fear, fueled by discussions around alleged associations with illicit activities and institutional capital outflows, even as a polarized community debates whether it presents a generational buying opportunity or further downside.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending after a substantial earnings miss fueled panic selling among investors, with many questioning management's execution. However, a segment of the community remains bullish, emphasizing the company's long-term pivot to AI infrastructure, secured power, and substantial financing for future growth despite current operational losses from the transition away from Bitcoin mining.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after launching a cheaper, compounded oral version of semaglutide, provoking immediate threats of legal and regulatory action from Novo Nordisk and the FDA. The community is sharply divided, with bulls seeing a bold move to expand access and bears criticizing it as an illegal infringement on patented drugs that could lead to significant financial and regulatory fallout.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending after its latest earnings report revealed a significantly higher-than-anticipated $200 billion in capital expenditures planned for 2026, predominantly for AI infrastructure and AWS expansion. While this massive investment fuels community debate over immediate margin pressures versus long-term growth opportunities, the market's strong negative reaction highlights broader concerns about tech sector spending.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is at the center of a broad tech sell-off, as Amazon's massive CapEx guidance for AI intensifies community fears of an 'AI bubble' and prompts widespread questioning of future returns. The market is gripped by a 'brutal' sentiment, fueled by accusations of manipulation and concerns that Bitcoin's sharp decline is dragging down the entire sector.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is actively discussed amid heightened broad market volatility, as investors react to a new Federal Reserve Chair nomination and conflicting geopolitical headlines, sparking a contentious debate between bulls anticipating a rebound and bears fearing a deeper sell-off.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

KELYB is trending as Hunt Equity's recent acquisition of over 92% of its Class B shares has drastically reduced the public float, fueling community-wide short squeeze speculation. Traders are keenly observing the extremely limited available shares and zero borrow rates, frequently comparing its volatile price action to past low-float runners.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Mounting geopolitical concerns in the Middle East, a sharp downturn in major tech stocks following earnings, and a significant crypto market correction are driving SPY's trend, with the community fiercely debating whether this signals a deeper market collapse or a "face-ripper" rebound.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is highly volatile amid intense speculation surrounding escalating US-Iran tensions and the evolving situation in Venezuela, leaving traders debating whether a geopolitical "war premium" or increased supply will ultimately dictate crude prices.

Liberty Global Ltd. engages in the provision of communications services. It offers broadband, video, and mobile communication solutions. It operates through the following segments: Sunrise, Telenet, VM Ireland, and Central and Other. The company was founded on July 27, 2022, and is headquartered in Hamilton, Bermuda.

Liberty Global Ltd - Ordinary Shares - Class B

Liberty Global plc - Ordinary Shares - Class B

Liberty Global Class B (LBTYB) is drawing attention from traders noting an Oversold RSI and Bullish Reversal Divergence on daily charts, sparking community speculation about a potential breakout, sometimes drawing parallels to other volatile "Class B" stocks. This trading interest unfolds as the company continues strategic moves, including the recent completion of its Telenet acquisition.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$RLYB I think the only risk with the Cohort 2 would be safety since it&#39;s 300mg versus 150mg in Cohort 1.  Obviously efficacy will be better at the higher dose.  They did test a single ascending dose of 300mg back in 2023 and it had no major safety issues, but that was a single dose, not weekly.   
More importantly, the company would have seen the 4 week data of Cohort 2 at the end of Dec (when they originally guided to release the data)....if there were major safety concerns I FEEL like they would have seen them after 4 weeks and would have had to release the &#39;bad&#39; news in December...it&#39;s an assumption but seems likely the hold up is either A). working out a deal or B). saw some minimal signs of antibodie creation and want to check at the 14 week mark to make sure no major issues that far out.   
As far as when to buy, I loaded up pre-RS just because afterwards 1:8 split the OS will be 5.25m and 81% is locked by tutes and insiders ..so free float will be less than 1M.

Ted Kramer

Brian Thomson

$RLYB I know that the first part of  the 116 trial  was  positive  -  however,  what  are  the  actual  odds  of  the  second  one  being  positive?  I  feel  like  there  is  a  lot  of  positive  sentiment  on  this  board without  much  data.   
 
All  that  being  said,  I  do  like  RLYB  quite  a  bit,  and  I  will  probably  take  a  position.  Do  yall  think  it  would  be  better  to  buy  before  or  after  the  split  tomorrow?

StockTwits Web

Rallybio Corp

Rail

 I think the only risk with the Cohort 2 would be safety since it's 300mg versus 150mg in Cohort 1.  Obviously efficacy will be better at the higher dose.  They did test a single ascending dose of 300mg back in 2023 and it had no major safety issues, but that was a single dose, not weekly.   
More importantly, the company would have seen the 4 week data of Cohort 2 at the end of Dec (when they originally guided to release the data)....if there were major safety concerns I FEEL like they would have seen them after 4 weeks and would have had to release the 'bad' news in December...it's an assumption but seems likely the hold up is either A). working out a deal or B). saw some minimal signs of antibodie creation and want to check at the 14 week mark to make sure no major issues that far out.   
As far as when to buy, I loaded up pre-RS just because afterwards 1:8 split the OS will be 5.25m and 81% is locked by tutes and insiders ..so free float will be less than 1M.

Bolt Biotherapeutics Inc

Vanda Pharmaceuticals Inc

VYNE Therapeutics Inc

Cyclerion Therapeutics Inc

Galecto Inc

BioAtla Inc

Barinthus Biotherapeutics PLC - ADR

It&#39;s also worth noting that they emailed me and a few other retail investors the first week of Jan and said 
 
&#39;Because RLYB116 is a long-acting molecule, we have to continue long term safety and efficacy follow up and various blood tests have to be finalized. Please rest assured we remain fully committed to RLYB116 and are looking forward to sharing the data as soon as we are in a position to do so&#39; 
 
I doubt if they saw negative data at the end of Dec they would email such a promising sounding response ...but can&#39;t say for sure.  Just following all the cookie crumbs.

It's also worth noting that they emailed me and a few other retail investors the first week of Jan and said 
 
'Because RLYB116 is a long-acting molecule, we have to continue long term safety and efficacy follow up and various blood tests have to be finalized. Please rest assured we remain fully committed to RLYB116 and are looking forward to sharing the data as soon as we are in a position to do so' 
 
I doubt if they saw negative data at the end of Dec they would email such a promising sounding response ...but can't say for sure.  Just following all the cookie crumbs.